Homologous or Heterologous COVID-19 Booster Regimens Significantly Impact Sero-Neutralization of SARS-CoV-2 Virus and Its Variants.
Homologous or Heterologous COVID-19 Booster Regimens Significantly Impact Sero-Neutralization of SARS-CoV-2 Virus and Its Variants.
复制标题
DOI：
10.3390/vaccines10081321
复制
发表时间：
2022-08-15
期刊：
影响因子：
7.8
通讯作者：
Putcharoen, Opass
中科院分区：
文献类型：
--
作者：
Buathong, Rome;Hunsawong, Taweewun;Wacharapluesadee, Supaporn;Guharat, Suriya;Jirapipatt, Ratthapat;Ninwattana, Sasiprapa;Thippamom, Nattakarn;Jitsatja, Anusara;Jones, Anthony R.;Rungrojchareonkit, Kamonthip;Lohachanakul, Jindarat;Suthangkornkul, Rungarun;Tayong, Kedsara;Klungthong, Chonticha;Fernandez, Stefan;Putcharoen, Opass
我们测定了125名医护人员针对SARS-CoV-2祖先毒株Delta和Omicron Variants of Concerns(VOCs)的中和抗体水平，这些医护人员接受了CoronaVac作为主要疫苗，后来接受了单一ChAdOx1或两个连续加强剂的组合，分别使用两剂ChAdOx1或ChAdOx1或BNT162b2作为主要和第二加强剂，或两剂BNT162b2。初次接种后12周的效价不足以中和所有毒株。在单一的ChAdOx1增强剂之后，第30天的中和水平差异很大，只有一小部分参与者在第7天和第30天对奥美康产生了中和滴度。两个剂量的ChAdOx1作为促进剂诱导的活性最低。ChAdOx1和BNT162b2的组合比两个剂量的ChAdOx1诱导的中和作用更强。两种剂量的BNT162b2作为促进剂对Omicron VOC的抑制活性最强。
We determined the levels of neutralizing antibodies against the SARS-CoV-2 ancestral strain, Delta and Omicron variants of concern (VOCs), in 125 healthcare workers who received CoronaVac as their primary vaccination and later received either a single ChAdOx1 or a combi-nation of two consecutive boosters using either two ChAdOx1 doses or a ChAdOx1 or BNT162b2 as the primary and second boosters, respectively, or two doses of BNT162b2. The titers 12 weeks after primary vaccination were inadequate to neutralize all strains. After a single ChAdOx1 booster, the levels of neutralization at Day 30 varied significantly, with only a small proportion of participants developing neutralizing titers against Omicron at Day 7 and 30. The two doses of ChAdOx1 as the booster induced the lowest activity. A combination ChAdOx1 and BNT162b2 induced greater neutralization than by two doses of ChAdOx1. Two doses of BNT162b2 as the booster had the maximal activity against Omicron VOC.
登录
查看更多内容
DOI：
10.1056/nejmoa2201570
发表时间：
2022-05-05
期刊：
The New England journal of medicine
影响因子：
--
作者：
通讯作者：
--
影响因子：
82.9
作者：
Li J;Hou L;Guo X;Jin P;Wu S;Zhu J;Pan H;Wang X;Song Z;Wan J;Cui L;Li J;Chen Y;Wang X;Jin L;Liu J;Shi F;Xu X;Zhu T;Chen W;Zhu F
通讯作者：
Zhu F
影响因子：
120.7
作者：
Britton, Amadea;Fleming-Dutra, Katherine E.;Verani, Jennifer R.
通讯作者：
Verani, Jennifer R.
DOI：
10.1038/s43856-022-00141-4
发表时间：
2022
期刊：
COMMUNICATIONS MEDICINE
影响因子：
--
作者：
Campos, Guilherme R F;Almeida, Nathalie Bonatti Franco;Filgueiras, Priscilla Soares;Corsini, Camila Amormino;Gomes, Sarah Vieira Contin;de Miranda, Daniel Alvim Pena;de Assis, Jessica Vieira;de Souza Silva, Thais Barbara;Alves, Pedro Augusto;da Rocha Fernandes, Gabriel;de Oliveira, Jaquelline Germano;Rahal, Paula;Grenfell, Rafaella Fortini Queiroz;Nogueira, Mauricio L
通讯作者：
Nogueira, Mauricio L
DOI：
10.1056/nejmoa2116063
发表时间：
2022-01-13
期刊：
The New England journal of medicine
影响因子：
--
作者：
Rosenberg ES;Dorabawila V;Easton D;Bauer UE;Kumar J;Hoen R;Hoefer D;Wu M;Lutterloh E;Conroy MB;Greene D;Zucker HA
通讯作者：
Zucker HA